SNYSanofi
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in Europe (n = 24)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Volatility (1 y)supports the score · percentile 98
- Gross profit growth / assets (5 y)weighs on the score · percentile 25
- EBIT / EVsupports the score · percentile 93
Red flags and notes
- Caution:Dividend outgrows earnings Dividends grew 5+ points a year faster than earnings over five years and the payout is above 75 %.
- Sources disagree Dividend or fundamental sources disagree beyond tolerance.
- Unverified dividend A high yield reported by a single source only, not yet cross-checked.
Our sources disagree or are incomplete for this instrument.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 11.1
- P/B
- 1.2
- EV/EBIT
- 15.3
- Free-cash-flow yield
- 8.3%
- Market cap (EUR)
- €866.4억
Profitability and debt
- Return on equity
- 10.5%
- Return on invested capital
- 7.5%
Dividends
- Dividend yield
- 6.09%
- Payout ratio
- 76%
- 5-year dividend growth (per year)
- 4.9%
- Years of dividend growth
- 3
Returns and risk
- 1 day
- +1.7%
- 1 month
- −8.2%
- 1 year
- −14.7%
- Volatility, 1 yr
- 22.5%
- Max drawdown, 1 yr
- −21.1%
- Beta
- 0.86
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 1 10월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 17 9월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 6 8월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 30 7월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 30 7월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 27 7월 2026
- Sanofi: 6-K — Report of a foreign private issuer
FactSEC EDGAR · Filing · 17 7월 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| Rating change | 7/10 | 7 · 3 | — | Available with Invest Pro | |
| Model portfolio change | 7/10 | 7 · 6 | — | Available with Invest Pro | |
| Rating change | 6 → 7/10 | 7 · 6 | — | Available with Invest Pro | |
| Model portfolio change | 6/10 | 7 · 2 | — | Available with Invest Pro | |
| First rating | 6/10 | 7 · 2 | Caution:Dividend outgrows earnings | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
여기서 계약 해지 · EU 소비자: 구매 후 14일 이내 취소 가능.